This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Referral criteria from primary care - FH (familial hypercholesterolaemia)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Referral criteria:

  • diagnosis and screening:
    • healthcare professionals should offer all adults with FH a referral to a specialist with expertise in FH for confirmation of diagnosis and initiation of cascade testing
    • healthcare professionals should offer all children and young people diagnosed with, or being investigated for, a diagnosis of FH a referral to a specialist with expertise in FH in children and young people. This should be in an appropriate child/young person-focused setting that meets the standards within the 'National service framework for children, young people and maternity services' (available from www.dh.gov.uk)
  • drug treatment in adults:
    • prescribing of drug therapy for adults with homozygous FH should be undertaken within a specialist centre

    • refer adults with FH to a specialist with expertise in FH if treatment with the maximum tolerated dose of a high-intensity statin and ezetimibe does not achieve a recommended reduction in LDL-C concentration of greater than 50% from baseline (that is, LDL-C concentration before treatment)

    • refer adults with FH to a specialist with expertise in FH for consideration for further treatment if they are assessed to be at very high risk of a coronary event, that is, if they have any of the following:
      • established coronary heart disease
      • a family history of premature coronary heart disease
      • two or more other cardiovascular risk factors (for example, they are male, they smoke, or they have hypertension or diabetes)

    • adults with FH with intolerance or contraindications to statins or ezetimibe should be offered a referral to a specialist with expertise in FH for consideration for treatment with either a bile acid sequestrant (resin), nicotinic acid, or a fibrate to reduce their LDL-C concentration

    • the decision to offer treatment with a bile acid sequestrant (resin), nicotinic acid or a fibrate in addition to initial statin therapy should be taken by a specialist with expertise in FH

    • offer people with FH a referral to a specialist with expertise in FH if they are experiencing side effects that compromise concordance with lipid-modifying drug therapy

  • drug treatment in children:
    • will be under the guidance of a specialist

Refer the person to an FH specialist service for DNA testing if they meet the Simon Broome criteria for possible or definite FH, or they have a DLCN score greater than 5 (2)

Inform all people who have an identified mutation diagnostic of FH that they have an unequivocal diagnosis of FH even if their LDL-C concentration does not meet the diagnostic criteria (2)

Notes:

  • NICE suggest (3)
    • that clinicians should onsider the possibility of familial hypercholesterolaemia and investigate as described in Familial hypercholesterolaemia if they have:
      • a total cholesterol concentration more than 7.5 mmol/litre
      • and a family history of premature coronary heart disease
    • arrange for specialist assessment of people with a total cholesterol concentration of more than 9.0 mmol/litre or a non-HDL cholesterol concentration of more than 7.5 mmol/litre even in the absence of a first-degree family history of premature coronary heart disease
  • most FH patients can be managed in primary care (4)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.